Markets:

Overview

News

Currencies

International

Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

4.260 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 22, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 13, 2025

From Verastem Oncology

Via Business Wire

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer ↗

May 08, 2025

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.

Via Benzinga

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased ↗

May 08, 2025

The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian...

Via Stocktwits

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 08, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology to Present at Upcoming Investor Conferences

May 01, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces $75 million Private Placement

April 25, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

April 23, 2025

From Verastem Oncology

Via Business Wire

9 Health Care Stocks With Whale Alerts In Today's Session ↗

April 22, 2025

Via Benzinga

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 10, 2025

Via Benzinga

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 07, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

March 25, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

March 20, 2025

From Verastem Oncology

Via Business Wire

Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

March 18, 2025

Via Benzinga

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket ↗

March 18, 2025

Via Benzinga

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

February 20, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

January 29, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

January 23, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

January 15, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

January 14, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

January 13, 2025

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 08, 2025

From Verastem Oncology

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 31, 2024

Via Benzinga

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday? ↗

December 31, 2024

Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025.

Via Benzinga

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

December 30, 2024

From Verastem Oncology

Via Business Wire

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

December 20, 2024

From Applied Therapeutics

Via GlobeNewswire

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

December 18, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

November 26, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

November 06, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

October 31, 2024

From Verastem Oncology

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.